Private financing · Biotech
Dren Bio closes $350 million financing for antibody therapy development
Juvia Group and Lightspeed co-led the investment in the clinical-stage biotechnology company.
Dren Bio closed a $350 million private financing announced on October 29, 2026. Juvia Group and Lightspeed co-led the round, joined by new and existing healthcare investors.
The capital will support late-stage development, regulatory submissions and a planned commercial launch for dibotatug, an investigational antibody therapy. It will also fund additional indications and the company’s wider oncology and autoimmune disease pipeline.
Use of funds
Dibotatug clinical development and regulatory submissions
Planned commercialization
Broader oncology and autoimmune pipeline development
Funding history
Private financing · This round$350M